Daily Rounds: Longevity & Healthcare Brief

Your daily briefing on the science of living longer, better. Covering the past 24 to 48 hours in longevity, medicine, and healthspan research.

Presented By Our Partners

🧠 NEUROLOGY & COGNITIVE HEALTH

🧠 Protein FTL1 Identified as a Key Driver of Brain Aging and Memory Decline

Scientists have uncovered FTL1, an iron-associated protein whose elevated levels in aging mice weakened connections between brain cells and accelerated memory decline. When researchers reduced FTL1 levels in older mice, synaptic function improved and memory test performance recovered, identifying a specific molecular target for preserving cognitive function. The study, published in Nature Aging, offers one of the clearest mechanistic links yet between a single molecule and age-related cognitive decline. 📌 Read more → ScienceDaily

🧠 Blood Test Predicts Alzheimer’s Progression Years Before Brain Scan Changes

A study by investigators at Mass General Brigham found that a blood test measuring plasma phosphorylated tau 217 (pTau217) can predict the progression of amyloid buildup and cognitive decline in cognitively healthy older adults, years before abnormalities appear on PET scans. The finding could shift Alzheimer’s screening from expensive imaging to routine blood draws, enabling earlier risk stratification at scale. 📌 Read more → Medical Xpress

🧠 GLP-1 Drug Researchers Propose Dropping GLP-1 as a Target Entirely

In a provocative turn, scientists whose work spurred the development of GLP-1 receptor agonists like Zepbound are now exploring whether effective weight loss can be achieved without targeting GLP-1 at all. An experimental drug activating GIP and glucagon receptors at high doses may produce comparable results with fewer side effects like nausea and vomiting, according to a peer-reviewed paper published this week by a team funded by BlueWater Biosciences. 📌 Read more → STAT News

❤️ CARDIOVASCULAR HEALTH

❤️ Single CRISPR Infusion Cuts LDL Cholesterol by 50% in First Human Trial

Cleveland Clinic’s Phase 1 trial of CTX310 showed that a single CRISPR-Cas9 gene editing infusion safely reduced LDL cholesterol by up to 49% and triglycerides by roughly 55% in 15 adults by targeting the ANGPTL3 gene. No serious safety events related to the treatment were reported across six trial sites. Phase 2 studies targeting broader populations are planned for 2026, bringing the prospect of a one-time cardiovascular risk intervention closer to reality. 📌 Read more → Cleveland Clinic

❤️ Lp(a) Emerges as the Next Major Cardiovascular Treatment Target

Elevated lipoprotein(a), an inherited form of cholesterol present in roughly 20% of the population, is gaining recognition as a leading driver of atherosclerotic cardiovascular disease that current therapies cannot address. Multiple Phase III trials including the Lp(a) HORIZON trial (8,000+ patients) and the OCEAN(a) Outcomes Trial are now underway to determine whether Lp(a) lowering with agents like pelacarsen and lepodisiran reduces major cardiac events. 📌 Read more → Harvard Gazette

❤️ Irregular Sleep Timing Linked to Cardiovascular and Metabolic Risk

A review published in Nature Reviews Cardiology highlights that disrupted circadian rhythms exacerbate hypertension, diabetes, and obesity even when total sleep duration is adequate. The evidence underscores that when you sleep may matter as much as how long you sleep for long-term cardiovascular resilience, positioning sleep regularity as a significant modifiable risk factor. 📌 Read more → Nature Reviews Cardiology

🦠 GUT MICROBIOME & IMMUNE HEALTH

🦠 The People You Live With May Be Reshaping Your Gut Microbiome

A new University of East Anglia study published in Molecular Ecology found that close social interactions drive the exchange of gut bacteria between individuals who share living spaces, regardless of whether their diets differ. Researchers studying Seychelles warblers found that birds sharing the closest social bonds had the most similar anaerobic gut bacteria, with findings suggesting that similar mechanisms of microbial exchange through physical proximity operate in humans. 📌 Read more → ScienceDaily

🦠 Gut Bacteria Molecule Doubles Lung Cancer Immunotherapy Response

University of Florida researchers identified a small compound called Bac429, produced naturally by gut bacteria, that doubled the response to lung cancer immunotherapy in mice. When injected into tumors with highly nonresponsive lung cancer, mice showed 50% less tumor growth after immunotherapy. Researchers envision this molecule as a drug that could be given alongside or before immune checkpoint therapy to boost patient responsiveness without adding invasive treatment. 📌 Read more → University of Florida

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

🦠 Phase III Trial Tests Microbiome Capsule Alongside Cancer Immunotherapy

UH Seidman Cancer Center launched a SWOG Phase III trial combining a once-daily microbiome capsule (CBM588) with immunotherapy for patients with advanced kidney cancer. Early phase results showed encouraging survival signals with no additional toxicity, marking one of the first large-scale clinical tests of a gut microbiome intervention as a standard oncology co-treatment. 📌 Read more → University Hospitals

🔬 CELLULAR HEALTH, SENOLYTICS & EPIGENETICS

🔬 Aging Researchers Shift Focus from Fixing Aging to Preserving Biological Coordination

At the 2nd World Congress on Targeting Longevity in Berlin, international researchers concluded that the next breakthrough in longevity science may not be a molecule or therapy but a deeper understanding of how biological systems communicate and lose balance over time. The emerging consensus treats aging as a systems-level loss of coordination involving mitochondrial signaling, microbiota-brain interactions, and metabolic repair environments rather than any single pathway. 📌 Read more → EurekAlert

🔬 FDA Clears First Human Trial of Epigenetic Reprogramming Therapy

Life Biosciences received FDA clearance for an Investigational New Drug application for ER-100, the first ever partial epigenetic reprogramming therapy to reach human clinical trials. The Phase 1 study will evaluate whether three transcription factors (OCT4, SOX2, KLF4) delivered locally to the eye can safely restore older and damaged retinal cells to a younger state in patients with optic neuropathies. The approach uses a doxycycline-inducible system for precise control over when the reprogramming genes are active. 📌 Read more → Life Biosciences

🔬 Senolytic Compounds Measurably Reduce Epigenetic Age in Lab Studies

A study published in npj Aging found that several senolytic compounds including JQ1, RG7112, nutlin-3a, and AMG232 significantly reduced epigenetic clock readings in vitro, suggesting their potential as both therapeutic agents and screening tools for anti-aging drug development. Early human pilot data suggest these drugs may lower biological age markers, with trials now exploring effects on mobility and cognition in older adults. 📌 Read more → npj Aging (Nature)

🤖 AI IN MEDICINE & DRUG DISCOVERY

🤖 Novo Nordisk Partners with OpenAI to Accelerate Drug Research

Novo Nordisk announced a partnership with OpenAI to apply advanced AI models to complex biological datasets and compress the time between scientific research and patient access to new medicines. The deal builds on Novo’s collaboration with Nvidia’s Gefion sovereign AI supercomputer and reflects a broader industry race to embed frontier AI into every stage of drug development. 📌 Read more → CNBC

🤖 More Than 173 AI-Discovered Drug Candidates Now in Clinical Trials

As of early 2026, more than 173 AI-discovered drug programs have entered clinical development with roughly 94 in Phase I, 56 in Phase II, and 15 in Phase III. Insilico Medicine’s lead compound moved from target identification to Phase I in under 30 months, compared to the industry average of four to six years. Between 15 and 20 AI-discovered programs are expected to enter pivotal trials this year. 📌 Read more → MedCity News

🤖 FDA Rethinks What Counts as a Breakthrough for AI Medical Devices

STAT News reports that the FDA has granted breakthrough designation to over 1,200 devices since 2016, many powered by AI. The agency is now raising the bar: algorithms that simply improve a doctor’s capabilities no longer qualify. Breakthrough AI devices must solve problems physicians cannot, signaling a shift from AI as a diagnostic aid to AI as an independent clinical capability, particularly in vascular imaging where algorithms achieve 84 to 95% sensitivity for pulmonary embolism detection. 📌 Read more → STAT News

⌚ WEARABLES, BIOMARKERS & PRECISION HEALTH

⌚ Rapid Melatonin Test Could Transform Circadian Health Monitoring

Researchers at Washington State University developed a 3D-printed smartphone reader using fluorescent nanoparticles that quantifies melatonin levels in just 15 minutes from a drop of blood, originally designed for astronauts monitoring their biological clocks in space. Published in Nanoscale Horizons, the technology could eventually give anyone a precise window into their circadian rhythm without a lab visit, transforming how shift workers and the general public track sleep-wake biology. 📌 Read more → WSU Insider

⌚ Digital Health Monitoring Devices Market Projected to Reach $35 Billion by 2035

The digital health monitoring devices market, valued at $7.4 billion in 2026, is projected to reach $35.12 billion by 2035 at a compound annual growth rate of 18.9%, driven by wearable biosensors gaining broader clinical adoption. Wearable patches and adhesive biosensors are the fastest-growing sub-segment, while platforms integrating heart rate variability, sleep patterns, and metabolic biomarkers are generating real-time cardiovascular risk scores. 📌 Read more → GlobeNewsWire

💪 MUSCLE MASS, STRENGTH & METABOLIC HEALTH

💪 ACSM Rewrites Resistance Training Guidelines for the First Time in 17 Years

The American College of Sports Medicine published its most comprehensive resistance training position stand ever, synthesizing 137 systematic reviews involving more than 30,000 participants. The headline finding: even simple bodyweight or elastic band routines meaningfully improve strength, muscle size, and physical function. The update explicitly confirms that training to failure is not required and that consistency matters far more than complexity. 📌 Read more → EurekAlert

💪 Every 10% Gain in Muscle Mass Cuts Insulin Resistance by 11%

Research confirms a strong dose-response relationship between skeletal muscle mass and insulin sensitivity: for every 10% increase in muscle, insulin resistance drops by 11%. Men who did no strength training were 2.4 times more likely to be insulin resistant than those training one to two hours per week. Clinicians are increasingly framing muscle building as a modifiable metabolic intervention with direct impact on blood sugar regulation. 📌 Read more → Fit Theories

🥗 NUTRITION & METABOLIC HEALTH

🥗 Low-Carb, High-Fat Diet Improves Metabolic Markers in Obese Older Adults in Eight Weeks

A study at the University of Alabama at Birmingham found that a very low-carbohydrate, high-fat dietary intervention produced meaningful improvements in body composition, fat distribution, and metabolic health markers in obese older adults over just eight weeks. Participants showed reductions in visceral fat alongside improved insulin sensitivity, adding to evidence that macronutrient composition can drive rapid metabolic change even in older populations. 📌 Read more → NaturalNews

🥗 Metabolic Eating and Fiber Diversity Emerge as Top Nutrition Strategies for 2026

Nutrition researchers are spotlighting fiber diversity, not just fiber quantity, as a key driver of gut health, metabolic function, and blood sugar regulation, with data supporting 25 to 38 grams daily as an optimal target. In parallel, 69% of surveyed nutrition professionals chose the Mediterranean diet as the most effective dietary approach for long-term health and weight management, reflecting a broader shift from weight-focused dieting toward metabolic health optimization. 📌 Read more → The Food Institute

😴 SLEEP & CIRCADIAN HEALTH

😴 Sleep Timing Irregularity in Midlife Linked to Major Cardiac Events Over 10 Years

A study published in BMC Cardiovascular Disorders found that irregular sleep timing in midlife is independently associated with incident major adverse cardiac events and cardiovascular disease mortality over a 10-year follow-up period. The data suggest that maintaining consistent sleep and wake times may be as important as total sleep duration for long-term cardiovascular protection. 📌 Read more → BMC Cardiovascular Disorders

😴 Circadian Disruption Mechanisms Mapped Across Cardiometabolic Disease

A comprehensive review in Circulation Research maps the pathways through which irregular sleep increases cardiometabolic risk, including circadian dysfunction, chronic inflammation, autonomic nervous system imbalance, HPA axis disruption, and gut dysbiosis. The evidence positions sleep regularity as one of the most underutilized modifiable risk factors in preventive cardiology, with implications for how clinicians counsel patients beyond the standard advice of sleeping seven to nine hours. 📌 Read more → Circulation Research

📌 TODAY’S TOP TAKEAWAYS

💪 ACSM Rewrites Resistance Training Guidelines: New evidence confirms that any amount of resistance training builds strength and muscle, even bodyweight exercises at home, with consistency mattering far more than complexity.
❤️ CRISPR Infusion Cuts Cholesterol by 50%: A single gene editing infusion safely halved LDL cholesterol in 15 adults, bringing one-time cardiovascular interventions closer to the clinic.
🦠 Housemates Shape Your Gut Microbiome: New research shows that daily physical interactions with the people you live with drive microbial exchange, regardless of shared diet.
🔬 First Epigenetic Reprogramming Therapy Enters Human Trials: The FDA cleared ER-100, the first partial reprogramming therapy to reach clinical testing, targeting optic neuropathies with cellular rejuvenation.
🧠 FTL1 Protein Drives Brain Aging: Scientists identified a specific protein whose reduction in older mice restored synaptic function and improved memory, opening a new therapeutic avenue for cognitive preservation.

Sources compiled from ScienceDaily, Medical Xpress, Cleveland Clinic, Harvard Gazette, Nature Reviews Cardiology, University of Florida, University Hospitals, EurekAlert, Life Biosciences, npj Aging, CNBC, MedCity News, STAT News, WSU Insider, GlobeNewsWire, BMC Cardiovascular Disorders, Circulation Research, STAT News, Fit Theories, NaturalNews, The Food Institute, and Mass General Brigham. Published: April 19, 2026.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

No spam. Unsubscribe anytime. We respect your inbox.